EUVIMEDEUVIMED entdecken
Crossref

Novel Purine‐Based Natural Products as Inhibitors of Cholinesterases and Monoamine Oxidases Presenting Potential Multitarget Therapeutics Tackling Alzheimer's Disease

Amira E Shaaban iD, Ahmed R Ali iD, Seif N Ayyad, Farid A Badria

Archiv der Pharmazie · 2025-07 · 358 (7)

DOI: 10.1002/ardp.70035 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Archiv der Pharmazie, online erschienen am 09.07.2025. Verfasst von Amira E Shaaban und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacognosy, Faculty of Pharmacy, Mansoura University, Mansoura, Egypt. Hauptthemen laut MEDLINE: Cholinesterase Inhibitors, Alzheimer Disease, Monoamine Oxidase Inhibitors, Biological Products. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 63 Literaturangaben. Gefördert von: This study is partly funded by Research Unit, Mansoura University (project code: MU-Phra-23-27). The authors would like to acknowledge the STDF (Science, Techn….

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Alzheimer's disease (AD) is a complex neurological disorder that arises from multiple factors. The innovative multitarget‐directed ligand (MTDL) approach, which incorporates multiple pharmacophores into one molecule, enhances the development of effective therapeutics for AD. Eighteen novel natural product‐based purine MTDLs were synthesized. These hybrids were evaluated In Vitro for their inhibitory effects on AChE, BChE, MAO‐A, and MAO‐B. The findings revealed that most hybrids effectively and selectively inhibited AChE. Hybrid 9b demonstrated the highest inhibitory potency against AChE, BChE, MAO‐A, and MAO‐B, exhibiting IC 50 values of 5.52, 11.64, 25.99, and 34.78 µM, respectively. In addition, hybrid 9b exhibited interesting antioxidant activity, with an IC 50 of 6.69 µM. The mechanism of action and the binding modes of hybrid 9b were analyzed through molecular docking studies. Molecular dynamics simulation revealed that hybrid 9b is stable within the AChE active site. In Silico assessments of physicochemical properties for hybrid 9b indicate that it is well absorbed following oral administration and can penetrate brain tissue. Finally, hybrid 9b stability studies in simulated gastric and intestinal conditions suggested that it could be absorbed into the bloodstream without significant degradation. Consequently, these findings reinforce the potential therapeutic applications of hybrid 9b as a multifunctional therapeutic candidate for addressing AD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cholinesterase InhibitorsAlzheimer DiseaseMonoamine Oxidase InhibitorsBiological ProductsPurinesMonoamine OxidaseHumansStructure-Activity RelationshipMolecular Docking SimulationMolecular StructureAcetylcholinesteraseDose-Response Relationship, DrugAntioxidantsButyrylcholinesteraseMolecular Dynamics SimulationAnimals

Stichwörter der Autor:innen

Alzheimer's diseaseMAO inhibitorsMTDLsacetylcholinesterase inhibitorsbutyrylcholinesterase inhibitorsmolecular dockingmolecular dynamicsmolecular hybridizationpurine scaffold

Substanzen

Cholinesterase InhibitorsMonoamine Oxidase InhibitorsBiological ProductsPurinesMonoamine OxidaseAcetylcholinesteraseAntioxidantsButyrylcholinesterase

Autor:innen und Institutionen

  • Department of Pharmacognosy, Faculty of Pharmacy, Mansoura University, Mansoura, Egypt.
  • Department of Pharmacognosy, Faculty of Pharmacy, Horus University, New Damietta, Egypt.
  • Department of Medicinal Chemistry, Faculty of Pharmacy, Mansoura University, Mansoura, Egypt.
  • Department of Organic Chemistry, Faculty of Science, Damietta University, New Damietta, Egypt.

ORCID-Profile: Amira E Shaaban, Ahmed R Ali

Förderung

  • This study is partly funded by Research Unit, Mansoura University (project code: MU-Phra-23-27). The authors would like to acknowledge the STDF (Science, Techn…

Zitieren

APA

Shaaban, A. E., Ali, A. R., Ayyad, S. N., & Badria, F. A. (2025). Novel Purine‐Based Natural Products as Inhibitors of Cholinesterases and Monoamine Oxidases Presenting Potential Multitarget Therapeutics Tackling Alzheimer's Disease. Archiv der Pharmazie, 358(7). https://doi.org/10.1002/ardp.70035

Vancouver

Shaaban AE, Ali AR, Ayyad SN, Badria FA. Novel Purine‐Based Natural Products as Inhibitors of Cholinesterases and Monoamine Oxidases Presenting Potential Multitarget Therapeutics Tackling Alzheimer's Disease. Archiv der Pharmazie. 2025;358(7). doi:10.1002/ardp.70035

BibTeX
@article{Shaaban2025,
  author = {Shaaban, Amira E and Ali, Ahmed R and Ayyad, Seif N and Badria, Farid A},
  title = {Novel Purine‐Based Natural Products as Inhibitors of Cholinesterases and Monoamine Oxidases Presenting Potential Multitarget Therapeutics Tackling Alzheimer's Disease},
  journal = {Archiv der Pharmazie},
  year = {2025},
  volume = {358},
  number = {7},
  doi = {10.1002/ardp.70035}
}
Kostenlos starten →